Phosphorylated α-synuclein as a potential biomarker for Parkinson's disease and related disorders

Expert Review of Molecular Diagnostics

Volumn 12, Issue 2, 2012, Pages 115-117

  Foulds, Penelope ^a   Mann, David M A ^b   Allsop, David ^a  

^a LANCASTER UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

synuclein; biomarker; blood; cerebrospinal fluid; multiple system atrophy; oligomers; Parkinson's disease; phosphorylated a synuclein; plasma

Indexed keywords

ALPHA SYNUCLEIN; SERINE;

AMINO TERMINAL SEQUENCE; BIOTINYLATION; BLOOD ANALYSIS; CLINICAL ASSESSMENT; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HUMAN; LEWY BODY; LONGITUDINAL STUDY; MOLECULAR GENETICS; MOTOR DYSFUNCTION; NEUROFIBRILLARY TANGLE; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; REVIEW; SHY DRAGER SYNDROME;

ALPHA-SYNUCLEIN; BIOLOGICAL MARKERS; HUMANS; IMMUNOASSAY; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PHOSPHOPROTEINS;

EID: 84857938647     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.12.5     Document Type: Review

References (20)

1. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science 296, 1991-1995 (2002). (Pubitemid 34627514)
2. Ferreira ST, Klein WL. The toxic oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol. Learn. Mem. 96, 529-543 (2011).
3. Spillantini MG, Crowther RA, Jakes R et al. a-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469-6473 (1998). (Pubitemid 28249037)
4. El-Agnaf OMA, Salem SS, Paleologou KE et al. a-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 17, 1945-1947 (2003).
5. Tokuda T, Salem SA, Allsop D et al. Decreased a-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349, 162-166 (2006). (Pubitemid 44331776)
6. El-Agnaf OMA, Salem SA, Paleologou KE et al. Detection of oligomeric forms of a-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20, 419-425 (2006). (Pubitemid 44933318)
7. Lee PH, Lee G, Park HJ et al. The plasma a-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J. Neural Transm. 113, 1435-1439 (2006). (Pubitemid 44435881)
8. Li QX, Mok SS, Laughton KM et al. Plasma a-synuclein is decreased in subjects with Parkinson's disease. Exp. Neurol. 204, 583-588 (2007). (Pubitemid 46497045)
9. Mollenhauer B, Cullen V, Kahn I et al. Direct quantification of CSF a-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213, 315-325 (2008).
10. Hong Z, Shi M, Chung KA et al. DJ-1 and a-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133, 713-726 (2010).
11. Shi M, Zabetianb CP, Hancocka AM et al. Significance and confounders of peripheral DJ-1 and a-synuclein in Parkinson's disease. Neurosci. Lett. 480, 78-82 (2010).
12. Anderson JP, Walker DE, Goldstein JM et al. Phosphorylation of Ser-129 is the dominant pathological modification of a-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739-29752 (2006). (Pubitemid 44536983)
13. Sato H, Arawaka S, Hara S et al. Authentically phosphorylated a-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J. Neurosci. 31, 16884-16894 (2011).
14. Foulds PG, Mann DMA, Mitchell JD et al. Progress towards a molecular biomarker for Parkinson disease. Nat. Rev. Neurol. 6, 359-361 (2010).
15. Foulds PG, Mitchell JD, Parker A et al. Phosphorylated a-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J. 25, 4127-4137 (2011).
16. Foulds PG, Yokota O, Thurston A et al. Post mortem cerebrospinal fluid a-synuclein levels are raised in multiple system atrophy and distinguish this from the other a-synucleinopathies, Parkinson's disease and dementia with Lewy bodies. Neurobiol. Dis. 45, 188-195 (2012).
17. Bartels T, Choi JG, Selkoe DJ. a-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107-110 (2011).
18. Prvulovic D, Hampel H. Amyloid b (Ab) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Clin. Chem. Lab Med. 49, 367-374 (2011).
19. Shaw LM, Vanderstichele H, Knapik-Czajka M et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65, 403-413 (2009).
20. Fukumoto H, Tokuda T, Kasai T et al. High-molecular weight b-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 24, 2716-2726 (2010).